BANK VONTOBEL/CALL/NOVO NORDISK ADR B/180/0.1/21.03.25 | Market Closed - Börse Stuttgart 07:19:10 28/06/2024 BST | ||
| 0.65 EUR | +1.56% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.65 | +1.56% |
| 27/06/24 | 0.64 | -8.57% |
| 26/06/24 | 0.7 | +16.67% |
| 25/06/24 | 0.6 | +1.69% |
| 24/06/24 | 0.59 | +1.72% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 07:19 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD7QV3 |
| ISIN | DE000VD7QV37 |
| Date issued | 10/06/2024 |
| Strike | 180 $ |
| Maturity | 21/03/2025 (264 Days) |
| Parity | 10 : 1 |
| Emission price | 0.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.7 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.01 € |
| Spread % | 1.64% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
